预约演示
Aditxt to acquire Appili Therapeutics
疫苗并购
The acquisition enhances the portfolio of Aditxt in precision diagnostics and infectious disease treatment. Credit: Gorodenkoff / Shutterstock.com.
Aditxt has announced a definitive agreement under which its subsidiary, Adivir, will acquire complete issued and outstanding Class A common shares of biopharmaceutical company Appili Therapeutics.
Aditxtve enhances Aditxt’s portfolio and creates synergies with its exisAdivirrogrammes, particularly in precision diagnostics.Appili Therapeutics
Founded in 2015, AAditxtdeveloped the Food and Drug Administration-approved LIKMEZ (ATI-1501).
LIKMEZ is a reforAppilid version of thFood and Drug Administrationhat improvLIKMEZieATI-1501ience and compliance by making the medication easier to swallow and better tasting.
LIKMEZ licensed the manufacturing and commercialisametronidazolef the product in the US and other selected territories to Saptalis Pharmaceuticals.
Forma Therapeutics gets grant for USP30 inhibitor compounds for medical use
Forma Therapeuticsgets grant for mUSP30 inhibitorUSP30-targeting complex inhibiting DUX4 expression with oligonucleotide payload
Appili is also advancing ATI-1701, a live attenuated vaccine for Francisella tularensis.
Dyne Therapeutics of Defense has supported the ATI-1701 biodefence prDUX4mme with $14m non-dilutive funding to progress the vaccine’s development.
Another key asset in Appili’s portfolio is ATI-1801, a topical formulation for cutaneous leishmaniasis.
The US Department of Defensetxt in bolstering iATI-1701olio and integrating precision diagnostics with tailored treatment strategies.
The closure of the acAppiliion will occur iATI-1801ird quarter of 2024.cutaneous leishmaniasis
Aditxt co-founder, chairman paromomycino Albanna stated: “The acquisition of Appili would represent another step in Aditxt’s journey towards advancing promising innovations in health.
“Our mission is to acceleAditxtome of the most promising health innovations, like those developed by Appili, to reach their full potential and to have a lasting impact.
“By integrating Appili’s proven expertise and diverse portfolio in the infectious disease and biodefence domain, Aditxt can substantially contribute to advancing public health solutions.”
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。